Completed PHASE4 INTERVENTIONAL 6-arm NCT05319756

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

A Phase 4 Randomized Double-blind Double-dummy Placebo & Active-controlled Single-dose Six-way Crossover Study Evaluating Abuse Potential of NEURONTIN® Taken Orally With Oxycodone HCL in Healthy Non-drug Dependent Recreational Opioid Users

Sponsor: Viatris Specialty LLC

Conditions Abuse Potential

Interventions gabapentin 1200 mg gabapentin 1200 mg and oxycodone HCl 20 mg gabapentin 600 mg gabapentin 600 mg and oxycodone HCl 20 mg oxycodone HCl 20 mg placebo

Updated 5 times since 2022 Last updated: Jul 21, 2023 Started: Apr 30, 2021 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Abuse Potential and is currently completed. Viatris Specialty LLC leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2023 — Jul 2024 [monthly]

Completed PHASE4
Mar 2023 — Sep 2023 [monthly]

Completed PHASE4
May 2022 — Mar 2023 [monthly]

Completed PHASE4

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viatris Specialty LLC

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marlton, United States